{"lc": {"ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds": {"story_link": "https://www.thepharmaletter.com/article/ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "user_code": "SAP_2", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-9-19 16:36:39", "close_timestamp": 1634657799375, "created": "19/10/2021 15:36:39", "department": "Computing", "disability": false, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-10-19", "gender": "male", "id": "f21f0394-f58a-48db-8206-7b4eb6e8d04d", "open_date_time": "2021-9-19 16:30:49", "open_timestamp": 1634657449496, "story_date": "2020-04-21 00:00:00", "story_source": "tpl", "story_title": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds", "summary": "Ivermectin can kill COVID-19 within 48 hours', Monash University study finds. Ummm... Dr Kylie Wagstaff said something intelligent, and some drugs did something.", "task_condition": "viz", "task_key": "ivermectin-can-kill-covid-19-within-48-hours-monash-university-study-finds", "task_level": "post_graduate_phd", "time_taken_in_seconds": 349879, "what": "drugs, virus, treatment, research", "when_happened": "few_years_ago", "where_location": "not sure", "who": "Kylie Wagstaff", "why": "not sure"}, "challenges-expected-for-novavax-covid-19-vaccine-in-usa": {"story_link": "https://www.thepharmaletter.com/article/challenges-expected-for-novavax-covid-19-vaccine-in-usa", "user_code": "SAP_2", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-9-19 16:23:21", "close_timestamp": 1634657001778, "created": "19/10/2021 15:23:22", "department": "Computing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-10-19", "gender": "male", "id": "513ea398-d9f9-4989-b4c6-6895fef15a38", "open_date_time": "2021-9-19 16:15:37", "open_timestamp": 1634656537738, "story_date": "2021-06-23 00:00:00", "story_source": "tpl", "story_title": "Challenges expected for Novavax COVID-19 vaccine in USA", "summary": "Novavax produced a new vaccine and tested it. It worked against certain variants (e.g. alpha & beta) but not others. The uptake projections look poor, but that's 'cos the yanks are a bit silly. Elsewhere people will use it. The company is going to file for approval to produce lots of doses", "task_condition": "text", "task_key": "challenges-expected-for-novavax-covid-19-vaccine-in-usa", "task_level": "post_graduate_phd", "time_taken_in_seconds": 464040, "what": "Vaccines development an uptake", "when_happened": "current_month", "where_location": "USA and Mexico", "who": "Nancy Jaser", "why": "Because the vaccine is effective against certain strains of covid-19"}, "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19": {"story_link": "https://www.thepharmaletter.com/article/australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "user_code": "SAP_2", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-9-19 16:41:17", "close_timestamp": 1634658077292, "created": "19/10/2021 15:41:16", "department": "Computing", "disability": false, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-10-19", "gender": "male", "id": "8375afe9-5ca6-46b7-93e7-e2d7a9da446d", "open_date_time": "2021-9-19 16:37:11", "open_timestamp": 1634657831911, "story_date": "2020-08-20 00:00:00", "story_source": "tpl", "story_title": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19", "summary": "Australian GPs urged to prescribe ivermectin triple therapy to fight COVID-19. The rest is a bit hard to figure out!", "task_condition": "viz", "task_key": "australian-gps-urged-to-prescribe-ivermectin-triple-therapy-to-fight-covid-19", "task_level": "post_graduate_phd", "time_taken_in_seconds": 245381, "what": "Australia, covid, treatment", "when_happened": "few_years_ago", "where_location": "Australia, covid, therapy, medication", "who": "Australian government", "why": "not sure"}, "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve": {"story_link": "https://www.thepharmaletter.com/article/japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "user_code": "SAP_2", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-9-19 16:30:28", "close_timestamp": 1634657428548, "created": "19/10/2021 15:30:29", "department": "Computing", "disability": false, "ease": 2, "environment": "production", "experiment_date_datepicker": "2021-10-19", "gender": "male", "id": "2294e778-0382-4b99-8b66-fe16537923c7", "open_date_time": "2021-9-19 16:23:41", "open_timestamp": 1634657021090, "story_date": "2020-07-21 00:00:00", "story_source": "tpl", "story_title": "Japan is first country to approve COVID-19 cocktail Ronapreve", "summary": "Roche produced a treatment for covid-19, and Japan's ministry of health has adopted it for public use. It has been shown to be effective in reducing the risk of hospitalization and death and is effective against a number of variants. It has also been adopted by other regions, including the EU", "task_condition": "text", "task_key": "japan-is-first-country-to-approve-covid-19-cocktail-ronapreve", "task_level": "post_graduate_phd", "time_taken_in_seconds": 407458, "what": "development and testing of a treatment for patients with covid-19", "when_happened": "few_years_ago", "where_location": "Japan", "who": "Levi Garraway, Osamu Okuda", "why": "Because the treatment is shown to be effective in trials and has been adopted by Japan's ministry of health"}}, "tb": {"pfizer": {"story_term": "pfizer", "user_code": "SAP_2", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-9-19 16:55:22", "close_timestamp": 1634658922684, "created": "19/10/2021 15:55:23", "department": "Computing", "disability": false, "ease": 1, "environment": "production", "experiment_date_datepicker": "2021-10-19", "gender": "male", "id": "47fdfc68-c07e-4ec1-a9b1-05ff31f75504", "open_date_time": "2021-9-19 16:41:32", "open_timestamp": 1634658092151, "summary": "Pfizer has been developing treatments and vaccines for covid-19 and has had a number of successes. First it has been successful in developing a vaccine for the Brazilian variant, which is more transmissible than other forms of the virus. Second, it has made progress in developing an oral antiviral treatment, and is working on an intravenous version. Third, the USFDA has given its approval for the vaccine that Pfizer developed with BioNTech to be made available to adolescents up to the ager of 15. ", "task_condition": "text", "task_key": "pfizer", "task_level": "post_graduate_phd", "time_taken_in_seconds": 830533}, "astrazeneca": {"story_term": "astrazeneca", "user_code": "SAP_2", "age_group": "51_plus", "agreed": true, "close_date_time": "2021-9-19 17:10:21", "close_timestamp": 1634659821623, "created": "19/10/2021 16:10:22", "department": "Computing", "disability": false, "ease": 3, "environment": "production", "experiment_date_datepicker": "2021-10-19", "gender": "male", "id": "6ede2809-1248-4877-910d-3a5b8cc54244", "open_date_time": "2021-9-19 16:55:46", "open_timestamp": 1634658946295, "summary": "AstraZeneca has delivered some strong results recently and performed well in the markets. For example, their 1st quarter 2021 results posted revenues of $7.3 billion, an increase of 15% year on year. Likewise, product sales grew 15% to 7,257 million, driven by sales across oncology and biopharmaceuticals. Finally, they recently completed trials of a treatment for severe asthma, which showed improvement over a placebo in reduction of symptoms. The results have been referred to as ground breaking and the market opportunity significant.", "task_condition": "viz", "task_key": "astrazeneca", "task_level": "post_graduate_phd", "time_taken_in_seconds": 875328}}}